SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-271108
Filing Date
2022-10-27
Accepted
2022-10-27 17:18:33
Documents
17
Period of Report
2022-10-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d421669d8k.htm   iXBRL 8-K 33182
2 EX-1.1 d421669dex11.htm EX-1.1 179852
3 EX-5.1 d421669dex51.htm EX-5.1 8318
4 EX-99.1 d421669dex991.htm EX-99.1 8598
8 GRAPHIC g421669dsp40.jpg GRAPHIC 4353
9 GRAPHIC g421669dsp42.jpg GRAPHIC 9499
  Complete submission text file 0001193125-22-271108.txt   433314

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA tsha-20221026.xsd EX-101.SCH 2853
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20221026_lab.xml EX-101.LAB 18740
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20221026_pre.xml EX-101.PRE 11706
11 EXTRACTED XBRL INSTANCE DOCUMENT d421669d8k_htm.xml XML 3468
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 221338228
SIC: 2836 Biological Products, (No Diagnostic Substances)